galegenimab：Galegenimab (FHTR 2163)
Galegenimab (FHTR 2163)
A Study Assessing the Safety
https://clinicaltrials.gov
This study will evaluate the safety, tolerability, and efficacy of intravitreal injections of galegenimab (FHTR2163) administered every 4 weeks (Q4W) or every 8 ...
Anti
https://www.abeomics.com
Anti-HTRA1(galegenimab biosimilar) mAb ; Clonality : Monoclonal ; Reactivity : Human ; Amount : 100 µg ; Isotype : IgG1 ; Purification : Purified from cell culture ...
Galegenimab - Genentech
https://adisinsight.springer.c
Galegenimab (formerly RO 7171009) intravitreal injection was being developed by Genentech (a subsidiary of Roche), for the treatment of patients with ...
galegenimab
https://www.guidetopharmacolog
Comment: Galegenimab is the INN that has been assigned to Genentech's anti-HTRA1 (HtrA serine peptidase 1) Fab antibody [6]. The antibody and its use are ...
VIDEO
https://www.healio.com
視網膜地圖狀萎縮藥開發難？羅氏撤二期候選抗體藥
https://news.gbimonthly.com
除了galegenimab以外，羅氏仍然有一些用於治療地圖狀萎縮的選擇，包括子公司基因泰克(Genentech)管理的1項臨床一期候選藥物，以及羅氏合作夥伴Lineage ...